Due to safety concerns, the US Food and Drug Administration has placed a warning on the use of transvaginal mesh in pelvic organ prolapse (POP) repair.1 Studies like the one by Chughtai et al2 in this issue of JAMA Surgery are important because they provide important information regarding the incidence and timing of complications. Compared with other studies, their work is unique for 2 reasons. First, it focuses on clinically important mesh complications (those that require an intervention as opposed to asymptomatic erosions). Second, it includes a statewide database, which minimizes underreporting that occurs when patients change clinicians secondary to perceived complications.
Davé BA, Boller A. Mesh—Is Less More?. JAMA Surg. 2017;152(3):263-264. doi:10.1001/jamasurg.2016.4201